Menu
Patient Coverage Patient Coverage

EXPLORE AURYXIA COVERAGE BY INDICATION

Depending on your patient’s type of insurance, they can get AURYXIA for little or no cost

Broad Insurance Coverage for Patients With Hyperphosphatemia in CKD on Dialysis

  • AURYXIA is covered by the majority of commercial plans
    • No prior authorizations
    • No step edits
  • The majority of patients with commercial insurance pay as little as $0 per fill of AURYXIA—with savings up to $500 per 30‑day fill. Click here for information on the Copay Program

Medicare LIS/dual eligible

  • AURYXIA is on formulary at all major Medicare Part D Plans
    • Prior authorization required to confirm diagnosis
  • All Medicare full Low-Income Subsidy (LIS)/dual-eligible patients pay no more than $10.00 per fill of AURYXIA

Standard medicare part d

  • AURYXIA is on formulary at all major Medicare Part D Plans
    • Prior authorization required to confirm diagnosis
    • Free AURYXIA may be provided to Medicare Part D patients who cannot afford their copays*

Uninsured Patients

  • Free AURYXIA may be provided to uninsured patients*

Insurance Coverage for Patients With Iron Deficiency Anemia in CKD Not on Dialysis

  • AURYXIA is covered by the majority of commercial plans
    • No prior authorizations
    • No step edits
  • The majority of patients with commercial insurance pay as little as $0 per fill of AURYXIA—with savings up to $500 per 30‑day fill. Click here for information on the Copay Program

Uninsured Patients

  • Free AURYXIA may be provided to uninsured patients*

Reimbursement help

Looking for personalized access assistance regardless of insurance type?

Call one of our dedicated AkebiaCares Case Managers

*Patients with an income of up to 400% Federal Poverty Level (FPL) may be eligible for free AURYXIA. Additional restrictions apply. For details, please contact an AkebiaCares Case Manager at 855-686-8601.

Reference: Data on File 24, Akebia Therapeutics, Inc.

INDICATIONS

AURYXIA® (ferric citrate) is indicated for:

  • The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis
  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS

The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)
  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information